CrossrefInfokarte
Reply to Letter to the Editor Regarding “Dosing Interval Extension of Dupilumab in CRSwNP: Five Year Real World Outcomes” by Meulmeester et al.
International Forum of Allergy & Rhinology · 2026-11 · 16 (11) · 1389-1391
DOI: 10.1002/alr.70293 ↗Abstract
Kein Abstract verfügbar.
EUVIMED